Table 3_Niraparib promotes ferroptosis by inhibiting TM4SF1 expression through ALKBH1-medi

46.1 KB of experimental results on the antitumor mechanism of niraparib in BRCA wild-type ovarian cancer models. The data, authored by Po-Wu Liu and last updated June 1, 2026, likely contains measurements of gene expression, 6mA modification levels, and ferroptosis markers from in vitro and in vivo assays.

Use Cases

• Analyze the relationship between ALKBH1 expression and TM4SF1 suppression based on epigenetic modification data.
• Model the correlation between TM4SF1 knockdown and tumor growth inhibition based on in vivo and in vitro assay results.
• Investigate the induction of ferroptosis based on Fe2+ accumulation and lipid ROS production measurements.

Strengths

• Data is associated with a detailed, peer-reviewed methodological description of experiments.
• The dataset is licensed under CC-BY-4.0 for open reuse.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The 46.1 KB file size suggests a limited scope of data.

Provenance

Source

figshare

Collection Method

Data likely originates from laboratory experiments including dot blot, ELISA, 6mA-IP-seq, RT-qPCR, Western blot, CCK-8 assay, colony formation, wound healing, Transwell assays, and subcutaneous tumor xenograft models.

Freshness

Last updated 2026-06-01 07:44:00; freshness should be verified.